Connor, Clark & Lunn Investment Management (CC&L)
JNCE

Connor, Clark & Lunn Investment Management (CC&L)’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,404
Closed -$28.5K – 1575
2023
Q1 		$28.5K Buy
+15,404
New +$19.1K ﹤0.01% 1206
2022
Q4 		– Sell
-144,885
Closed -$339K – 1483
2022
Q3 		$339K Buy
144,885
+18,812
+15% +$66.6K ﹤0.01% 893
2022
Q2 		$382K Sell
126,073
-45,051
-26% -$219K ﹤0.01% 830
2022
Q1 		$1.16M Sell
171,124
-3,614
-2% -$25.8K 0.01% 629
2021
Q4 		$1.46M Buy
174,738
+53,840
+45% +$444K 0.01% 606
2021
Q3 		$898K Buy
120,898
+48,302
+67% +$299K ﹤0.01% 663
2021
Q2 		$494K Sell
72,596
-12,599
-15% -$105K ﹤0.01% 791
2021
Q1 		$875K Sell
85,195
-9,734
-10% -$107K ﹤0.01% 719
2020
Q4 		$665K Sell
94,929
-5,457
-5% -$42.5K ﹤0.01% 688
2020
Q3 		$819K Sell
100,386
-79,178
-44% -$491K 0.01% 656
2020
Q2 		$1.24M Sell
179,564
-4,524
-2% -$24.4K 0.01% 562
2020
Q1 		$874K Sell
184,088
-2,400
-1% -$13.8K 0.01% 586
2019
Q4 		$1.63M Sell
186,488
-1,700
-0.9% -$9.19K 0.01% 459
2019
Q3 		$627K Buy
188,188
+12,050
+7% +$48.2K ﹤0.01% 627
2019
Q2 		$872K Sell
176,138
-8,100
-4% -$43K 0.01% 598
2019
Q1 		$1.14M Buy
184,238
+15,928
+9% +$77K 0.01% 503
2018
Q4 		$567K Buy
168,310
+38,780
+30% +$181K ﹤0.01% 672
2018
Q3 		$842K Buy
129,530
+53,955
+71% +$401K ﹤0.01% 597
2018
Q2 		$579K Buy
+75,575
New +$1.09M ﹤0.01% 743

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s JNCE Position: Q2 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 15,404 shares — an estimated $28.5K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in JNCE in Q2 2018 and held it in 19 quarters. The position peaked at $1.63M in Q4 2019. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 15,404 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $28.5K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 19 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Jounce Therapeutics, Inc. Common Stock position peaked at $1.63M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2023, filed 10 Aug 2023.